These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17419828)

  • 21. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Current state of research on multiple sclerosis].
    Lubina-Dabrowska N; Stepień A; Chalimoniuk M
    Pol Merkur Lekarski; 2013 Mar; 34(201):135-9. PubMed ID: 23700821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
    Correale J; Cristiano E
    Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
    Goodin DS; Frohman EM; Garmany GP; Halper J; Likosky WH; Lublin FD; Silberberg DH; Stuart WH; van den Noort S;
    Neurology; 2002 Jan; 58(2):169-78. PubMed ID: 11805241
    [No Abstract]   [Full Text] [Related]  

  • 25. Multiple sclerosis: monotherapy rules.
    Hauser SL; Josephson SA; Johnston SC
    Ann Neurol; 2013 Mar; 73(3):A5-6. PubMed ID: 23596013
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study.
    Ghezzi A;
    Neurol Sci; 2005 Dec; 26 Suppl 4():S183-6. PubMed ID: 16388355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis.
    Sternberg Z; Leung C; Sternberg D; Yu J; Hojnacki D
    Cardiovasc Ther; 2014 Apr; 32(2):33-9. PubMed ID: 24119301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of interferon Beta and glatiramer acetate in multiple sclerosis.
    Goodin DS
    Semin Neurol; 2013 Feb; 33(1):13-25. PubMed ID: 23709209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacologic management of multiple sclerosis.
    Blasier MG
    Urol Nurs; 2008 Jun; 28(3):217-9. PubMed ID: 18605517
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of immunomodulatory treatment of multiple sclerosis on lymphocyte surface immunomarkers.
    Michałowska-Wender G; Losy J; Wender M; Januszkiewicz-Lewandowska D; Nowak J
    Pol J Pharmacol; 2003; 55(5):877-80. PubMed ID: 14704481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment.
    García-Barragán N; Villar LM; Espiño M; Sádaba MC; González-Porqué P; Alvarez-Cermeño JC
    Eur J Neurol; 2009 Mar; 16(3):380-5. PubMed ID: 19175382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High prevalence and no latitude gradient of multiple sclerosis in Norway.
    Berg-Hansen P; Moen SM; Harbo HF; Celius EG
    Mult Scler; 2014 Nov; 20(13):1780-2. PubMed ID: 24603884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG].
    Rieckmann P; Toyka KV
    Eur Neurol; 1999; 42(3):121-7. PubMed ID: 10529535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Experience in the treatment of multiple sclerosis with interferon beta in Galicia].
    Romero-López J; Seijo-Martínez M; Del Campo V; Amigo-Jorrín MC; Arias M; Cortés-Laíño JA; Dapena-Bolaño D; López-González FJ; Lorenzo-González JR; Marín-Sánchez M; Muñoz-García D; Ozaita-Arteche G; Prieto JM
    Rev Neurol; 2003 Dec 1-15; 37(11):1001-4. PubMed ID: 14669137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Quality of life of patients receiving long-term treatment with first-line disease-modifying drugs: results of a Russian multicenter study using MusiQoL].
    Boĭko OV; Popova EV; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):86-92. PubMed ID: 24300820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Place of residence determines access to interferon-beta therapy in MS. Less than 15 per cent of patients are treated--big differences between the counties].
    Andersson A; Persson PM; Fredrikson S
    Lakartidningen; 1999 Dec; 96(49):5492-5. PubMed ID: 10643243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
    Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC
    Value Health; 2004; 7(5):554-68. PubMed ID: 15367251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.